---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000010"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:58:18.293497+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)

## Summary
- Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.
- One-year survival rate 68.1% vs 60.2% (p=0.029).
- Median pain-free survival 15.2 months vs 9.1 months; 6.1-month extension (HR 0.74, p=0.027).
- TTFields therapy well-tolerated with mild to moderate skin adverse events; no new safety signals.
- Company plans to file for FDA PMA approval in second half of 2025.

## SEC filing metadata
- accession: 0001645113-25-000010
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000010/0001645113-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000010/nvcr-20250531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000010
- JSON: https://secwatch.observer/filing/0001645113-25-000010.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.